
There may be differences between this version and the published version. You are advised to consult the published version if you wish to cite from it.

[http://eprints.gla.ac.uk/269487/](http://eprints.gla.ac.uk/269487/)

Deposited on 21 April 2022

Enlighten – Research publications by members of the University of Glasgow
[http://eprints.gla.ac.uk](http://eprints.gla.ac.uk)
**Full Title:** Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF)

**Short title:** Effect of empagliflozin on kidney perfusion in HFrEF

**Correspondence:** Professor Patrick Mark
British Heart Foundation Glasgow Cardiovascular Research Centre
Institute of Cardiovascular and Medical Sciences
126 University Place
University of Glasgow
Glasgow, G12 8TA
United Kingdom

Tel: +44 (0)141 330 8218

Email: patrick.mark@glasgow.ac.uk

ORCID: 0000-0003-3387-2123

**Article type:** Research letter **Total Word Count:** 800 (main text)

This work was presented as a late-breaking clinical trial abstract at the American Society of Nephrology Kidney Week, November 4-7, 2021.

**Twitter handle:** @MetaMedTeam; @UoGHeartFailure

**Short tweet:** Empagliflozin reduces kidney perfusion in patients with HFrEF
BACKGROUND

Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce risk of worsening kidney function in patients with heart failure and reduced ejection fraction (HFrEF). Comparatively little is known about effects of these drugs on kidney perfusion in the setting of randomized controlled trials. We studied effects of these drugs using kidney magnetic resonance imaging (MRI).

METHODS

We conducted a randomized, double-blind, placebo-controlled trial investigating effects of empagliflozin in patients with NYHA functional class II to IV, left ventricular ejection fraction (LVEF) ≤40% and type 2 diabetes or prediabetes. Patients were randomized 1:1 to empagliflozin 10 milligrams daily or placebo. The study design, screening and consent process, ethical approvals, and main results are published.

Prespecified outcomes included change from baseline to 36 weeks in kidney MRI biomarkers (kidney perfusion measured by both arterial spin labelling (ASL) and magnetic resonance renography (MRR), kidney pre-contrast longitudinal relaxation time (T1), kidney apparent extracellular volume (aECV) (post-contrast T1) and total kidney volume) and soluble biomarkers (eGFR CKD-EPI creatinine, urinary albumin creatinine ratio (ACR), urinary sodium concentration, fractional excretion of sodium (FENa), and urinary potassium concentration).

Integrated gadolinium contrast-enhanced cardio-kidney MRI (MAGNETOM Prisma 3T scanner, Siemens, Erlangen, Germany) was performed at baseline and week 36. Reproducibility kidney MRI analyses are published elsewhere.

2
could not be aligned within the same coronal oblique view, the right kidney was prioritized. For ASL, T1 and aECV, regions of interest (ROIs) were drawn manually around the whole kidney, cortex, and an area of user-defined representative cortex. For MRR and kidney volumes, ROIs were drawn around the whole kidney. Observers were blinded to subject ID, scan date, clinical data and randomization arm. The primary results analyses excluded patients in atrial fibrillation/flutter at week 36 to avoid cardiac image degradation. For kidney analyses, we included patients in atrial fibrillation/flutter at week 36.

RESULTS

105 patients were randomized: mean age 68.7 [SD 11.1] years, 77 (73.3%) male, 82 (78.1%) diabetes and 23 (21.9%) prediabetes, mean LVEF 32.5% [9.8%], mean eGFR CKD-EPI creatinine 67.6 [22.1] mL/min/1.73 m², and median urinary ACR 11 (interquartile range 2-45) mg/g. Of 52 patients randomized to empagliflozin, 45 remained on randomized therapy and underwent baseline and 36-week MRI. Of 53 patients randomized to placebo, 50 remained on randomized therapy and underwent baseline and 36-week MRI.

Compared with placebo, empagliflozin reduced right whole kidney perfusion (ASL) by 25 (95% CI, -47 to -4, P=0.021) mL/100mL/min (Figure 1), reduced right whole kidney aECV by 4.8 (-8.8 to -0.8; P=0.020) %, and reduced urinary sodium concentration by 14 (-25 to -3; P=0.012) mmol/L. Similar results were seen for right cortex, left whole kidney, left cortex kidney perfusion (ASL) and left whole kidney aECV. There were no between-group differences in MRR (although directionally concordant), kidney T1
(right whole kidney), total kidney volume, eGFR CKD-EPI creatinine, urinary ACR, FENa or urinary potassium concentration at 36 weeks.

Within each randomization group compared to baseline, for empagliflozin, ASL was unchanged: right whole kidney (p=0.55), left whole kidney (p=0.45), right cortex (p=0.69), left cortex (p=0.33). With placebo, ASL was unchanged in the right whole kidney (p=0.059), left whole kidney (p=0.07) and left cortex (p=0.14) but increased in the right cortex (p=0.038). In the empagliflozin group, right kidney (p=0.0094) and both kidney (p=0.013) MRR decreased but not left kidney MRR (p=0.058). In the placebo group, right kidney (p=0.24), left kidney (p=0.33) and both kidney (p=0.25) MRR was unchanged.

**DISCUSSION**

ASL was unchanged in the empagliflozin group. ASL of the right cortex increased in the placebo group, which is an unexpected, possibly chance finding. The placebo-corrected finding of ASL reduction with empagliflozin compared to placebo is hypothesis-generating. There were directionally concordant changes in kidney perfusion by MRR. These changes suggest possible protective effects against glomerular hyperfiltration with reduction in ASL as a surrogate of intraglomerular perfusion. Sustained reduction seen in kidney perfusion (ASL) over 36 weeks is consistent with trajectories of kidney function observed in SGLT2 inhibitor outcome trials in HFrEF, with eGFR in the SGLT2 inhibitor group initially lower than the placebo group until 76 weeks (EMPEROR-Reduced) and 86 weeks (DAPA-HF). Empagliflozin reduced kidney aECV, which we speculate represents kidney ‘decongestion’ by reduction in renal interstitial fluid.
We know of few other trials examining effects of SGLT2 inhibition on kidney mechanisms in heart failure; these trials (NCT03027960, NCT03226457, NCT03198585,) had shorter follow-up duration of 14, 48 and 90 days respectively. To our knowledge, this is the first kidney MRI trial using SGLT2 inhibition in HFrEF. Other trials assess SGLT2 inhibition with kidney MRI, although are in patients without heart failure (NCT03093103, NCT04193566, ChiCTR2000037951).

CONCLUSIONS

Empagliflozin reduced kidney perfusion measured by ASL, with directionally concordant changes in MRR, and reduced aECV in patients with HFrEF and type 2 diabetes or prediabetes. Reduction in kidney perfusion and/or congestion may be mechanisms by which SGLT2 inhibitors affect kidney function in HFrEF.


Key Words: empagliflozin, SGLT2 inhibitors, heart failure, diabetes mellitus, prediabetes, mechanisms, clinical trial, MRI, hyperfiltration, randomized controlled trials, renal hemodynamics

Figure Legend

Figure 1. Change in Kidney Perfusion (ASL, MRR) and aECV from Baseline to Week 36. Data presented as mean and error bars represent 95% CIs. Treatment effect calculated using an analysis of covariance model adjusted for treatment group, age at baseline, diabetes status and baseline value. aECV indicates apparent extracellular
volume, ASL indicates arterial spin labelling, MRI indicates magnetic resonance imaging; and MRR, magnetic resonance renography.

Authors:

Matthew M. Y. Lee, MBChB1,2,3
Keith A. Gillis, PhD1,2
Katriona J. M. Brooksbank, PhD1
Sarah Allwood-Spies, PhD4
Pauline Hall-Barrientos, PhD4
Kirsty Wetherall, BSc5
Giles Roditi, MBChB1,2,3
Bashair AlHummiyany, MSc6
Colin Berry, PhD1,2
Ross T. Campbell, PhD1,2
Victor Chong, MD7
Liz Coyle1
Kieran F. Docherty, MBChB1,2
John G. Dreisbach, MBChB8
Bernd Kuehn, PhD9
Catherine Labinjoh, MD10
Ninian N. Lang, MBChB, PhD1,2
Vera Lennie, MD11,12
Kenneth Mangion, PhD1,2
Alex McConnachie, PhD
Clare L. Murphy, MBChB
Colin J. Petrie, PhD
John R. Petrie, PhD
Kanishka Sharma, PhD
Steven Sourbron, PhD
Iain A. Speirits, MSc
Joyce Thompson
Paul Welsh, PhD
Rosemary Woodward, BSc
Ann Wright, BSc
Aleksandra Radjenovic, PhD
John J. V. McMurray, MD
Pardeep S. Jhund, PhD
Mark C. Petrie, MBChB
Naveed Sattar, MD, PhD
Patrick B. Mark, PhD

* These authors contributed equally.

Affiliations:

1Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK
2Queen Elizabeth University Hospital, Glasgow, UK
3Glasgow Royal Infirmary, UK
4Department of Clinical Physics and Bioengineering, NHS Greater Glasgow and
Clyde, UK

5 Robertson Centre for Biostatistics, University of Glasgow, UK

6 University of Leeds, UK

7 University Hospital Crosshouse, Kilmarnock, UK

8 Golden Jubilee National Hospital, Glasgow, UK

9 Siemens Healthcare GmbH, Erlangen, Germany

10 Forth Valley Royal Hospital, Larbert, UK

11 University Hospital Ayr, Ayr, UK

12 Aberdeen Royal Infirmary, Aberdeen, UK

13 Royal Alexandra Hospital, Paisley, UK

14 University Hospital Monklands, Airdrie, UK

15 University of Sheffield, UK

16 West Glasgow Ambulatory Care Hospital, UK
Sources of Funding

This trial was supported by an investigator-initiated study grant from Boehringer Ingelheim. Boehringer Ingelheim has provided support in terms of funding and investigational medicinal product (IMP). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or decision to submit the manuscript for publication.

Dr Gillis, Dr Roditi, and Dr Mark hold a grant for studying clinical use of renal MRI imaging funded by Kidney Research UK (KS_IN_002_20180913).

Dr Berry, Dr McMurray, Dr M.C. Petrie, and Dr Sattar are supported by a British Heart Foundation Centre of Research Excellence Grant (RE/18/6/34217).

Dr Berry has received research support from the British Heart Foundation (PG/17/2532884, FS/17/26/32744, and RE/18/6134217) and the Medical Research Council (MR/S005714/1).

Dr Mangion was supported by a British Heart Foundation Clinical Training Fellowship (FS/15/54/31639).

Dr Sourbron was supported by the Innovative Medicines Initiative 2 Joint Undertaking (no. 115974, BEAt-DKD) and the Medical Research Council (MR/P023398/1, HEPARIM study [Hepatectomy Risk Assessment With Functional Magnetic Resonance Imaging]).
Disclosures

Dr Lee’s employer, the University of Glasgow, has received grant support from Boehringer Ingelheim.

Dr Gillis reports personal fees from Napp, AstraZeneca and Vifor.

Dr Berry is employed by the University of Glasgow, which holds consultancy and research agreements with companies that have commercial interests in the diagnosis and treatment of ischemic heart disease, including Abbott Vascular, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, HeartFlow, Menarini Farmaceutica, Opsens, Philips, and Siemens Healthcare.

Dr Docherty’s employer, the University of Glasgow, is paid by AstraZeneca for involvement in the DAPA-HF trial.

Dr Kuehn is an employee of Siemens Healthcare GmbH.

Dr Lang has received consultancy fees from AstraZeneca and Pharmacosmos and speaker’s fees from Roche, Pfizer and Novartis. He receives grant support from Roche Diagnostics (paid to his employer, the University of Glasgow).

Dr J.R. Petrie has received research grants from the Juvenile Diabetes Research Foundation. He has also received personal fees and travel support from Novo Nordisk and Merck KGaA (Germany), personal fees from Abbott, ACI Clinical, Biocon, and IQVIA, and nonfinancial support from AstraZeneca, Dexcom, Merck KGaA (Germany), and Itamar Medical.
Dr Sourbron reports research funding from European Federation of Pharmaceutical Industries and Associations (EFPIA) through the Innovative Medicines Initiative, and from Bayer AG, GlaxoSmithKline and General Electric for co-funded PhD studentships.

Mr Speirits reports speaker fees from AstraZeneca, BMS-Pfizer, Daiichi-Sankyo, Novartis and Servier, and advisory board fees from Boehringer Ingelheim.

Dr Welsh reports grant income from Roche Diagnostics, AstraZeneca, and Novartis, and speaker fees from Novo Nordisk, outside the submitted work.

Dr McMurray’s employer, the University of Glasgow, has been paid by AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, DalCor, GSK, Merck Sharp & Dohme, Novartis, Resverlogix, and Theracos for his participation in clinical trials and by Alnylam, AstraZeneca, Cardurion, Novartis, and Pfizer for consultancy, advisory board membership, or lectures.

Dr Jhund’s employer, the University of Glasgow, is paid by AstraZeneca for involvement in the DAPA-HF and DELIVER trials. He has also received consulting, advisory board, and speaker’s fees from Novartis and AstraZeneca, advisory board fees from Cytokinetics, and a grant from Boehringer Ingelheim.

Dr M.C. Petrie has received research grants or consultancy fees from SQ Innovations, AstraZeneca, Roche, Boehringer Ingelheim, Pharmacosmos, Eli Lilly, Napp Pharmaceuticals, Novartis, and Novo Nordisk and has served on clinical events committees for AbbVie, Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Resverlogix, and Novo Nordisk.
Dr Sattar has consulted for or received lecture fees from Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, and Sanofi. He has received grant support from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics through his institution, the University of Glasgow.

Dr Mark reports research funding from Boehringer Ingelheim, paid advisory boards and or lecture fees from AstraZeneca, Astellas, Napp, Vifor-Fresenius, Novartis, Pharmacosmos and travel support from Pharmacosmos, Napp and Vifor.

University of Glasgow and National Health Service Greater Glasgow and Clyde Trust have a master research agreement with Siemens Healthcare to use the renal arterial spin labelling work-in-progress sequence.
REFERENCES


![Figure 1.](image-url)